SCYNEXIS is a small biopharmaceutical company focused on developing antifungal drugs for serious fungal infections. The company's work centers on a novel class of antifungal agents called fungerps, which inhibit the same enzyme as existing echinocandin drugs but are structurally distinct, giving them activity against drug-resistant strains. SCYNEXIS has two core assets. The first is ibrexafungerp (BREXAFEMME), the first approved fungerp, which SCYNEXIS licensed to GSK in 2023 for commercialization in most markets. BREXAFEMME is FDA-approved for treatment and prevention of vulvovaginal candidiasis, and SCYNEXIS earns royalties and milestones on GSK's sales. GSK is planning a U.S. relaunch of BREXAFEMME and expects to initiate FDA discussions in 2026. The second asset is SCY-247, a second-generation fungerp in early clinical development in both oral and IV formulations, targeting invasive candidiasis and antifungal prophylaxis in immunocompromised patients such as cancer and transplant patients. SCY-247 has received FDA QIDP status and Fast Track designation for its oral formulation, providing at least 10 years of regulatory exclusivity if approved. SCYNEXIS does not manufacture drugs itself and has only 18 employees, making it essentially a drug development and licensing company. Revenue comes from milestone payments and royalties rather than direct drug sales, with near-term cash generation depending heavily on payments from GSK.